GENNEXT TECHNOLOGIES, INC.

Half Moon Bay, CA · Medtech · Private

LC-Fox™ Protein Footprinting System – a bench-top liquid chromatography instrument that combines hydroxyl radical footprinting with chromatographic separation to analyze dynamic conformational heterog

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · gnxtech.com

Sector: Medtech
Headquarters: Half Moon Bay, CA
Total capital: $16.4M

Federal grants: $16.4M; 19 awards · 2017–2025; Rank in peer group#16 of 538
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 6; 5 pending · first 2020; Rank in peer group#97 of 538

Capital timeline

Latest events

May 2025Federal grantHealth and Human S · Phase II · Multi-Radical Protein Footprinting (MRPF™) Platform$1.2M
May 2024Federal grantHealth and Human S · Phase II · Multi-Radical Protein Footprinting (MRPF™) Platform$1.3M
Apr 2023Federal grantHealth and Human S · Phase I · Liquid Chromatography Flash Oxidation (LC-Fox™) Protein Footprinting System$350K
Mar 2023Federal grantHealth and Human S · Phase II · Software for Determining Proteoform Heterogeneity and Protein Expression Fidelity$592K
Feb 2023Federal grantHealth and Human S · Phase II · In-cell Automated Flash Oxidation (IC-AutoFox™) Protein Footprinting System$1.2M
Mar 2022Federal grantHealth and Human S · Phase II · In-cell Automated Flash Oxidation (IC-AutoFox™) Protein Footprinting System$2.5M
Mar 2022Federal grantHealth and Human S · Phase II · Software for Determining Proteoform Heterogeneity and Protein Expression Fidelity$643K

Show 12 earlier federal awards

Jan 2022Federal grantHealth and Human S · Phase II · FoxWare™, An Advanced Data Analysis Package for Hydroxyl Radical Foot-Printing Higher Order Structural Analysis$471K
May 2021Federal grantHealth and Human S · Phase I · Multi-Wavelength Fluorescence Radical Dosimetry for Real-Time Assessment of Protein Footprinting Radical Yield$251K
Apr 2021Federal grantHealth and Human S · Phase II · Software for Determining Proteoform Heterogeneity and Protein Expression Fidelity$1.7M
Jan 2021Federal grantHealth and Human S · Phase II · FoxWare™, An Advanced Data Analysis Package for Hydroxyl Radical Foot-Printing Higher Order Structural Analysis$492K
Apr 2020Federal grantHealth and Human S · Phase I · In-Cell Radical Dosimetry (ICRD) for improved in vivo Fast Photo-oxidation of Proteins Hydroxyl Radical Protein Footprinting$262K
Feb 2020Federal grantHealth and Human S · Phase II · Tailoring the Hydroxyl Radical Foot-Printing Approach to Provide a Solution for the Higher Order Structural Analysis Needs of the Biopharmaceutical Industry$997K
Feb 2020Federal grantHealth and Human S · Phase II · FoxWare™, An Advanced Data Analysis Package for Hydroxyl Radical Foot-Printing Higher Order Structural Analysis$1.4M
Apr 2019Federal grantHealth and Human S · Phase II · Tailoring the Hydroxyl Radical Foot-Printing Approach to Provide a Solution for the Higher Order Structural Analysis Needs of the Biopharmaceutical Industry$2.1M
Jan 2019Federal grantHealth and Human S · Phase I · Software for Determining Proteoform Heterogeneity and Protein Expression Fidelity$225K
Apr 2018Federal grantHealth and Human S · Phase I · Metal-oxide Photo-Oxidation of Proteins (MoPOP) for Biopharmaceutical Higher Order Structural Analysis$225K
Jan 2018Federal grantHealth and Human S · Phase I · FoxWare, An Advanced Data Analysis Package for Hydroxyl Radical Foot-Printing Higher Order Structural Analysis$224K
Sep 2017Federal grantHealth and Human S · Phase I · Tailoring the Hydroxyl Radical Footprinting Approach to Provide a Solution for the Higher Order Structural Analytical Needs of the Biopharmaceutical Industry$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 538 peers

Line = median

Medtech · Device

Federal grants#16 · top 3%
Granted patents#97 · top 18%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 6 granted of 11

Apr 1, 2025GrantedOpto-Fluidic Array for Radical Protein Foot-PrintingUSPTOUS 12,263,477
Jan 30, 2025PendingOpto-Fluidic Array for Radical Protein Foot-PrintingUSPTOApplication 18914273
Jun 25, 2024GrantedIn Vivo Radical Dosimetry And In Vivo Hydroxyl Radical Protein Foot-printingUSPTOUS 12,016,688

Show all 11 patent records

Opto-Fluidic Array for Radical Protein Foot-PrintingApr 1, 2025 · US 12,263,477Granted
Opto-Fluidic Array for Radical Protein Foot-PrintingJan 30, 2025 · Application 18914273Pending
In Vivo Radical Dosimetry And In Vivo Hydroxyl Radical Protein Foot-printingJun 25, 2024 · US 12,016,688Granted
Radical Dosimetry Methods For In Vivo Hydroxyl Radical Protein Foot-printingJun 18, 2024 · US 12,013,401Granted
Radical Dosimetry Methods For In Vivo Hydroxyl Radical Protein Foot-printingJun 18, 2024 · US 12,013,400Granted
Radical Dosimetry for Analysis of Biopharmaceuticals and Biological MoleculesNov 23, 2021 · US 11,181,529Granted
Flash Photo-oxidation Device And Higher Order Structural AnalysisOct 27, 2020 · US 10,816,468Granted
Opto-fluidic Array For Radical Protein Foot-printingApplication PCTUS2021060394Pending
In Vivo Radical Dosimetry And In Vivo Hydroxyl Radical Protein Foot-printingApplication PCTUS2020012430Pending
Radical Dosimetry For Analysis Of Biopharmaceuticals And Biological MoleculesApplication PCTUS2019057059Pending
Flash Photo-oxidation Device And Higher Order Structural AnalysisApplication PCTUS2018034682Pending

BioLum Sciences, LLCSimilar federal contract value in Medtech · null in contracts
RIZLAB HEALTH, INC.Similar federal contract value in Medtech · null in contracts
IMMUNOWORK, LLCSimilar federal contract value in Medtech · null in contracts
ALERJE, INC.Similar federal contract value in Medtech · null in contracts
Vigilant Diagnostics LLCSimilar federal contract value in Medtech · null in contracts
ZYMERON CORPORATIONSimilar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.